Cv Sciences, Inc. (CVSI) — SEC Filings
Cv Sciences, Inc. (CVSI) — 23 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 14 8-K, 5 10-Q, 2 DEF 14A.
View Cv Sciences, Inc. on SEC EDGAR
Overview
Cv Sciences, Inc. (CVSI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: CV Sciences, Inc. reported a net loss of $382,000 for the three months ended September 30, 2025, a slight improvement from the $456,000 net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $752,000, significantly better than the $1,668,000 loss in the p
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 1 bearish, 22 neutral. The dominant filing sentiment for Cv Sciences, Inc. is neutral.
Filing Type Overview
Cv Sciences, Inc. (CVSI) has filed 5 10-Q, 14 8-K, 2 DEF 14A, 2 10-K with the SEC between Mar 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of CVSI's 22 recent filings, 1 were flagged as high-risk, 14 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $10.482M |
| Net Income | -$752K |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | $381K |
| Operating Margin | Not Disclosed |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- Dr. Michael L. Smith
Industry Context
The hemp-derived CBD market is highly competitive and subject to evolving regulatory landscapes. Recent legislative changes, such as the upcoming THC limit, are creating uncertainty and could lead to market consolidation. Companies like CV Sciences must navigate these regulatory shifts while facing declining sales and pressure on margins.
Top Tags
material-agreement (5) · financials (5) · 10-Q (4) · financial-reporting (3) · 8-K (3) · CV Sciences (3) · filing (2) · filing-update (2) · 10-K (2) · litigation (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product Sales, Net (Q3 2025) | $3.256M | Decreased from $3.865M in Q3 2024, a 15.8% decline. |
| Product Sales, Net (YTD Sept 2025) | $10.482M | Decreased from $11.821M in YTD Sept 2024, an 11.3% decline. |
| Net Loss (Q3 2025) | $382K | Improved from $456K net loss in Q3 2024. |
| Net Loss (YTD Sept 2025) | $752K | Significantly improved from $1.668M net loss in YTD Sept 2024. |
| Net Cash Flows Used in Operating Activities (YTD Sept 2025) | $53K | Represents negative cash flow from operations, indicating liquidity strain. |
| Accumulated Deficit (Sept 30, 2025) | $87.7M | Indicates significant historical losses and raises going concern doubts. |
| Cash (Sept 30, 2025) | $381K | Decreased from $454K at Dec 31, 2024, highlighting dwindling liquidity. |
| Net Proceeds from Secured Promissory Note (Oct 2025) | $300K | Recent capital injection to fund operations, but a short-term solution. |
| THC Limit | 0.4 milligrams | New federal legislation effective Nov 13, 2026, impacting hemp-derived products. |
| Commission File Number | 000-54677 | Identifies the company's SEC filing history. |
| IRS Employer Identification No. | 80-0944970 | Company's tax identification number. |
| Period End Date | 2025-03-31 | The 10-Q covers financial results up to this date. |
| Filing Date | 2025-05-14 | The date the 10-Q was officially submitted to the SEC. |
| Prior Year Quarter End | 2024-03-31 | Used for comparative financial analysis. |
| Fiscal Year End | 2024-12-31 | The period covered by the 10-K filing. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cv Sciences, Inc. (CVSI)?
Cv Sciences, Inc. has 23 recent SEC filings from Mar 2024 to Nov 2025, including 14 8-K, 5 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CVSI filings?
Across 23 filings, the sentiment breakdown is: 1 bearish, 22 neutral. The dominant sentiment is neutral.
Where can I find Cv Sciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cv Sciences, Inc. (CVSI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cv Sciences, Inc.?
Key financial highlights from Cv Sciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CVSI?
The investment thesis for CVSI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cv Sciences, Inc.?
Key executives identified across Cv Sciences, Inc.'s filings include Dr. Michael L. Smith.
What are the main risk factors for Cv Sciences, Inc. stock?
Of CVSI's 22 assessed filings, 1 were flagged high-risk, 14 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Cv Sciences, Inc.?
Forward guidance and predictions for Cv Sciences, Inc. are extracted from SEC filings as they are enriched.